PD-1/PD-L1 Pathway: A Therapeutic Target in CD30+ Large Cell Lymphomas

Next generation sequencing of breast implant‐associated anaplastic large cell lymphomas reveals a novel STAT3‐JAK2 fusion among other activating genetic alterations within the JAK‐STAT pathway

(2021) Andrés E. Quesada et al.   Breast Journal

Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study

(2021) John Kuruvilla et al.   LANCET ONCOLOGY

PD-L1 expression in peripheral T-cell lymphomas is not related to either PD-L1 gene amplification or rearrangements

(2021) Rebeca Manso et al.   LEUKEMIA & LYMPHOMA

Immunity reloaded: Deconstruction of the PD-1 axis in B cell lymphomas

(2021) Karolina Bednarska et al.   BLOOD REVIEWS

A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas

(2021) Miso Kim et al.   HAEMATOLOGICA

Successful treatment of refractory retroperitoneal Epstein-Barr virus-positive diffuse large B-cell lymphoma with secondary hemophagocytic syndrome by sequential combination regimen of PD-1 blockade and chimeric antigen receptor T cells

(2021) Min Yu et al.   ANTI-CANCER DRUGS

Primary mediastinal Large B-cell Lymphoma

(2021) Kerry J. Savage   BLOOD

EBV‐positive HIV‐associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic features

(2021) Jennifer R. Chapman et al.   BRITISH JOURNAL OF HAEMATOLOGY

Breast implant-associated anaplastic large cell lymphoma: clinical follow-up and analysis of sequential pathologic specimens of untreated patients shows persistent or progressive disease

(2021) Mark G. Evans et al.   MODERN PATHOLOGY

EBV‐positive B‐cell lymphomas and lymphoproliferative disorders: Review from the perspective of immune escape and immunodeficiency

(2021) Akira Satou et al.   Cancer Medicine

The PD-1/PD-L1 Checkpoint in Normal Germinal Centers and Diffuse Large B-Cell Lymphomas

(2021) Marcos Garcia-Lacarte et al.   Cancers

Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial

(2021) Alex F. Herrera et al.   Blood Advances

Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified

(2021) Estelle Bourbon et al.   Blood Advances

Phase 2 Study of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-Hodgkin Lymphomas

(2021) Elif Yilmaz et al.   BLOOD

PD-L1/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphoma

(2020) Masaharu Kawashima et al.   LEUKEMIA

T-cell lymphoma secondary to checkpoint inhibitor therapy

(2020) Kartik Anand et al.   Journal for ImmunoTherapy of Cancer

Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report

(2020) Stuart E. Lacy et al.   BLOOD

A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications

(2020) George W. Wright et al.   CANCER CELL

PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas

(2020) Wei Xie et al.   Current Hematologic Malignancy Reports

STAT3 Mutation Is Associated with STAT3 Activation in CD30+ ALK− ALCL

(2020) Emma I. Andersson et al.   Cancers

PD-1: Its Discovery, Involvement in Cancer Immunotherapy, and Beyond

(2020) Yasumasa Ishida   Cells

Pembrolizumab followed by AVD in untreated early unfavorable and advanced stage classical Hodgkin lymphoma

(2020) Pamela Blair Allen et al.   BLOOD

Enhancing antitumor immunity through checkpoint blockade as a therapeutic strategy in T-cell lymphomas

(2020) Alexander Neuwelt et al.   Blood Advances

Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study

(2019) Stephen M. Ansell et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial

(2019) Yuankai Shi et al.   Lancet Haematology

Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma

(2019) Shahrzad Jalali et al.   Blood Cancer Journal

STAT-3 RNAscope Determination in Human Diffuse Large B-Cell Lymphoma

(2019) Roberto Tamma et al.   Translational Oncology

Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas

(2019) Keisuke Kataoka et al.   LEUKEMIA

Identification of high‐risk DUSP 22 ‐rearranged ALK ‐negative anaplastic large cell lymphoma

(2019) Greg Hapgood et al.   BRITISH JOURNAL OF HAEMATOLOGY

PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T cell-inflamed phenotype

(2019) James Godfrey et al.   BLOOD

Recurrent PDL1 expression and PDL1 (CD274) copy number alterations in breast implant-associated anaplastic large-cell lymphomas

(2019) Valentina Tabanelli et al.   HUMAN PATHOLOGY

A novel model of controlling PD-L1 expression in ALK+ anaplastic large cell lymphoma revealed by CRISPR screening

(2019) Jing-Ping Zhang et al.   BLOOD

Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma

(2019) Anja Mottok et al.   BLOOD

Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087

(2019) Robert Chen et al.   BLOOD

A single-arm, multicenter, phase 2 study of camrelizumab in relapsed or refractory classical Hodgkin lymphoma

(2019) Yuqin Song et al.   CLINICAL CANCER RESEARCH

Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study

(2019) Pier Luigi Zinzani et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study

(2019) Yuqin Song et al.   LEUKEMIA

PD-L1 expression is associated with ALK positivity and STAT3 activation, but not outcome in patients with systemic anaplastic large cell lymphoma

(2019) Jing Shen et al.   MODERN PATHOLOGY

Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant-associated ALCL.

(2019) Camille Laurent et al.   BLOOD

Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma

(2019) Philippe Armand et al.   JOURNAL OF CLINICAL ONCOLOGY

Hodgkin lymphoma: a review of pathological features and recent advances in pathogenesis

(2019) Miguel A. Piris et al.   PATHOLOGY

Epstein–Barr virus-associated B-cell lymphoproliferative disorders and lymphomas: a review

(2019) Mario L. Marques-Piubelli et al.   PATHOLOGY

Epstein–Barr virus-positive diffuse large B-cell lymphoma features disrupted antigen capture/presentation and hijacked T-cell suppression

(2019) Xiang-Nan Jiang et al.   OncoImmunology

EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2018 update on diagnosis, risk-stratification and management

(2018) Jorge J. Castillo et al.   AMERICAN JOURNAL OF HEMATOLOGY

Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL

(2018) Frank Vari et al.   BLOOD

Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma

(2018) Enrico Tiacci et al.   BLOOD

Biology of classical Hodgkin lymphoma: implications for prognosis and novel therapies

(2018) Anja Mottok et al.   BLOOD

Genetic subtyping of breast implant-associated anaplastic large cell lymphoma

(2018) Naoki Oishi et al.   BLOOD

Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes

(2018) Poonam K. Panjwani et al.   HUMAN PATHOLOGY

Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements

(2018) Rebecca A. Luchtel et al.   BLOOD

DUSP22-rearranged anaplastic lymphomas are characterized by specific morphological features and a lack of cytotoxic and JAK/STAT surrogate markers

(2018) Arantza Onaindia et al.   HAEMATOLOGICA

Frequent activating STAT3 mutations and novel recurrent genomic abnormalities detected in breast implant-associated anaplastic large cell lymphoma

(2018) Piers Blombery et al.   Oncotarget

PD-1/PD-L1 inhibitors in haematological malignancies: update 2017

(2017) Tomas Jelinek et al.   IMMUNOLOGY

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma

(2017) Robert Chen et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma

(2017) V Atsaves et al.   LEUKEMIA

Efficacy of nivolumab in a patient with systemic refractory ALK+ anaplastic large cell lymphoma

(2017) Charlotte Rigaud et al.   PEDIATRIC BLOOD & CANCER

Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2

(2017) Krzysztof M. Zak et al.   STRUCTURE

PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome

(2017) Hashem O. Alsaab et al.   Frontiers in Pharmacology

Pembrolizumab for relapsed anaplastic large cell lymphoma after allogeneic haematopoietic stem cell transplantation: efficacy and safety

(2016) Thomas S. Y. Chan et al.   ANNALS OF HEMATOLOGY

Nivolumab for Refractory Anaplastic Large Cell Lymphoma: A Case Report

(2016) Holger Hebart et al.   ANNALS OF INTERNAL MEDICINE

Comprehensive characterization of programmed death ligand structural rearrangements in B-cell non-Hodgkin lymphomas

(2016) L. C. Chong et al.   BLOOD

PD-1 blockade modulates chimeric antigen receptor (CAR)–modified T cells: refueling the CAR

(2016) Elise A. Chong et al.   BLOOD

Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas

(2016) K. Georgiou et al.   BLOOD

Immune checkpoint blockade: Releasing the brake towards hematological malignancies

(2016) Yi Xia et al.   BLOOD REVIEWS

Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study

(2016) S. Dubois et al.   CLINICAL CANCER RESEARCH

Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas

(2016) Thomas Menter et al.   HUMAN PATHOLOGY

Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant–Associated Anaplastic Large-Cell Lymphoma

(2016) Mark W. Clemens et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome

(2016) Margaretha G.M. Roemer et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

(2016) Anas Younes et al.   LANCET ONCOLOGY

Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers

(2016) Keisuke Kataoka et al.   NATURE

PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications

(2016) Wei Xing et al.   Oncotarget

The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation

(2016) Kankana Bardhan et al.   Frontiers in Immunology

EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment

(2015) A. Nicolae et al.   BLOOD

Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma

(2015) J. Kiyasu et al.   BLOOD

Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma

(2015) Ramona Crescenzo et al.   CANCER CELL

Integrated copy number and gene expression profiling analysis of epstein-barr virus-positive diffuse large b-cell lymphoma

(2015) Heejei Yoon et al.   GENES CHROMOSOMES & CANCER

Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas

(2015) Dohee Kwon et al.   HISTOPATHOLOGY

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 Blockade Can Restore Functions of T-Cells in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma In Vitro

(2015) Lina Quan et al.   PLoS One

Expression of Programmed Cell Death 1 Ligand 2 (PD-L2) Is a Distinguishing Feature of Primary Mediastinal (Thymic) Large B-cell Lymphoma and Associated With PDCD1LG2 Copy Gain

(2014) Min Shi et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Chemoresistance can be overcome with high-dose chemotherapy and autologous stem-cell transplantation for relapsed and refractory Hodgkin lymphoma†

(2014) A. S. Gerrie et al.   ANNALS OF ONCOLOGY

ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes

(2014) E. R. Parrilla Castellar et al.   BLOOD

Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma

(2014) David D. W. Twa et al.   BLOOD

Gene expression profiling of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly reveals alterations of characteristic oncogenetic pathways

(2014) Harumi Kato et al.   CANCER SCIENCE

Selective JAK2 Inhibition Specifically Decreases Hodgkin Lymphoma and Mediastinal Large B-cell Lymphoma Growth In Vitro and In Vivo

(2014) Y. Hao et al.   CLINICAL CANCER RESEARCH

Prevalence and Clinical Implications of Epstein-Barr Virus Infection in De Novo Diffuse Large B-Cell Lymphoma in Western Countries

(2014) C. Y. Ok et al.   CLINICAL CANCER RESEARCH

Clinical Implications of Phosphorylated STAT3 Expression in De Novo Diffuse Large B-cell Lymphoma

(2014) C. Y. Ok et al.   CLINICAL CANCER RESEARCH

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma

(2013) M. Boi et al.   BLOOD

PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies

(2013) B. J. Chen et al.   CLINICAL CANCER RESEARCH

Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial

(2012) K. L. Tan et al.   BLOOD

Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas

(2012) G. Vasmatzis et al.   BLOOD

Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation

(2012) M. Gupta et al.   BLOOD

Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy

(2012) M. R. Green et al.   CLINICAL CANCER RESEARCH

Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496)

(2012) Leo I. Gordon et al.   JOURNAL OF CLINICAL ONCOLOGY

EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation

(2012) Santiago Montes-Moreno et al.   MODERN PATHOLOGY

Programmed Death Ligand 1 Is Expressed by Non-Hodgkin Lymphomas and Inhibits the Activity of Tumor-Associated T Cells

(2011) D. J. Andorsky et al.   CLINICAL CANCER RESEARCH

Eight Cycles of Escalated-Dose BEACOPP Compared With Four Cycles of Escalated-Dose BEACOPP Followed by Four Cycles of Baseline-Dose BEACOPP With or Without Radiotherapy in Patients With Advanced-Stage Hodgkin's Lymphoma: Final Analysis of the HD12 Trial of the German Hodgkin Study Group

(2011) Peter Borchmann et al.   JOURNAL OF CLINICAL ONCOLOGY

MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers

(2011) Christian Steidl et al.   NATURE

Lestaurtinib Inhibition of the JAK/STAT Signaling Pathway in Hodgkin Lymphoma Inhibits Proliferation and Induces Apoptosis

(2011) Tania Diaz et al.   PLoS One

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma

(2010) M. R. Green et al.   BLOOD

Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma

(2010) Christian Steidl et al.   NEW ENGLAND JOURNAL OF MEDICINE

B7-H1 expression is regulated by MEK/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma

(2009) Ryo Yamamoto et al.   CANCER SCIENCE

Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival

(2009) Simone Muenst et al.   HUMAN PATHOLOGY

B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells

(2008) T. Azuma et al.   BLOOD

Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)

(2008) M. Marzec et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA